Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $57,590.52 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 348 shares of Twist Bioscience stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $165.49, for a total value of $57,590.52. Following the transaction, the insider directly owned 73,303 shares of the company’s stock, valued at $12,130,913.47. The trade was a 0.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The stock was sold at an average price of $122.62, for a total transaction of $50,519.44.

Twist Bioscience Price Performance

TWST stock opened at $182.83 on Friday. The firm has a 50 day moving average of $126.89 and a 200-day moving average of $87.13. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $186.20. The firm has a market capitalization of $11.47 billion, a P/E ratio of -82.36 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same period last year, the company posted $0.33 EPS. The business’s revenue was up 23.2% on a year-over-year basis. As a group, sell-side analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Large investors have recently modified their holdings of the business. QRG Capital Management Inc. purchased a new position in Twist Bioscience during the 2nd quarter valued at about $277,000. Engineers Gate Manager LP purchased a new stake in Twist Bioscience in the 2nd quarter worth approximately $3,333,000. Integrated Wealth Concepts LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $99,000. Allworth Financial LP grew its position in shares of Twist Bioscience by 54.9% in the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after buying an additional 213 shares during the last quarter. Finally, Nykredit A S purchased a new position in shares of Twist Bioscience during the second quarter valued at approximately $283,000.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TWST shares. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a research report on Monday, July 6th. BWS Financial restated a “sell” rating and issued a $45.00 target price on shares of Twist Bioscience in a research note on Friday, September 18th. Barclays raised their price target on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Finally, Piper Sandler upped their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $103.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.